Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;135(Suppl 1):45-52.
doi: 10.1007/s00508-023-02171-x. Epub 2023 Apr 20.

[Injection therapy of diabetes]

[Article in German]
Monika Lechleitner  1 , Michael Roden  2   3   4 , Raimund Weitgasser  5   6 , Bernhard Ludvik  7 , Peter Fasching  8 , Friedrich Hoppichler  9 , Alexandra Kautzky-Willer  10 , Guntram Schernthaner  11 , Rudolf Prager  12 , Susanne Kaser  13 , T C Wascher  14 ; Ausschuss Leitlinien
Affiliations

[Injection therapy of diabetes]

[Article in German]
Monika Lechleitner et al. Wien Klin Wochenschr. 2023 Jan.

Abstract
in English, German

The present article is a recommendation of the Austrian Diabetes Association for the practical use of injection therapy (GLP1-receptor agonists and insulin) in type 2 diabetes.

Die vorliegende Leitlinie nimmt Bezug auf die Indikation und praktische Umsetzung der Injektionstherapie (GLP1-Rezeptor Agonisten und Insulin) bei Typ 2 Diabetes.

Keywords: Injection therapy and type 2 diabetes mellitus.

PubMed Disclaimer

References

    1. American Diabetes Association Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S140–S157. - PMC - PubMed
    1. Singh S, Wright jr. EE, Kwan AYM, et al. Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2017;19:228–238. doi: 10.1111/dom.12805. - DOI - PMC - PubMed
    1. Frias JP. Prioritising injectable therapies in the management of type 2 diabetes. Lancet Diabetes Endocrinol. 2019;7:505–508. doi: 10.1016/S2213-8587(19)30117-2. - DOI - PubMed
    1. Alexopoulos A, Buse JB. Initial injectable therapy in type 2 diabetes: key considerations when chosing between glucagon-like pepetide 1 receptor agonists and insulin. Metabolism. 2019;98:104–111. doi: 10.1016/j.metabol.2019.06.012. - DOI - PMC - PubMed
    1. Abd El Aziz MS, Kahle M, Meier JJ, Nauck MA. Meta-analysis comparing clinical effects of short- or long-acting GLP-1-receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab. 2017;19:216–227. doi: 10.1111/dom.12804. - DOI - PubMed

Publication types